ERBB2 and ovarian cancer: HER2-targeted therapies, including the antibody trastuzumab and the tyrosine kinase inhibitor lapatinib, have shown some efficacy towards certain HER2-overexpressing ovarian cancers, but eventually acquired resistance to these therapies was also observed [6].